Fecal short-chain fatty acids and clinical outcomes in advanced melanoma treated with nivolumab plus ipilimumab: the Study of Combined nivolumab and ipilimumab therapy and Fecal biomarkers in Advanced melanoma (SCFA study) (ESMO Asia 2026) - Oct 1, 2026 - Abstract #673P; Pres time: Dec 4, 2026; 05:15 PM - 06:15 PM; Location: Poster area (Exhibition); No abstract available
Biomarker • Clinical • Clinical data • Metastases • Melanoma • Oncology • Solid Tumor
|
|
Tomoki Saito; Motoo Nomura; Kenjiro Namikawa; Yasuhiro Nakamura; Yukiko Kiniwa; Takuya Miyagawa; Yoshitsugu Shibayama; Manabu Muto
|